AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used S
In 2017, MSD made the decision to open a $1.32 billion, 220,000 sq ft research facility in the heart of London’s ‘knowledge quarter’ around King’s Cross.
Eli Lilly has said it plans to file its anti-IL-23p19 antibody mirikizumab for approval as a treatment for Crohn’s disease next year after it hit all its targets in a phas
Eli Lilly has struck a $2.4 billion deal to buy Dice Therapeutics and its drug discovery and development platform for oral, small molecule therapies for immunological dise
Grünenthal has been awarded a breakthrough designation from the FDA for its experimental painkiller resiniferatoxin, striving to become a treatment option that avoids the
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl